OS Therapies Inc (OSTX) company profile
Close on Nov 13, 2026Market cap $34.36MP/E –Yield –
About OS Therapies
Pharmaceutical Preparations, SIC 2834
OS Therapies Incorporated is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments for osteosarcoma and other solid tumors. Its pipeline features two core technologies: OST-HER2, an off-the-shelf immunotherapy utilizing an attenuated strain of Listeria monocytogenes to stimulate an immune response against HER2-expressing cancer cells, and a preclinical tunable antibody-drug conjugate platform known as OST-tADC. Beyond human oncology indications such as pediatric osteosarcoma, breast, lung, and esophageal cancers, the company explores veterinary applications in canines. Its intended patient populations include children, young adults, and older patients diagnosed with bone and solid cancers.
The company operates clinical development programs across major hospitals in the United States, including a completed Phase IIb trial conducted across 21 clinical sites in 18 U.S. states. Preclinical research collaborations extend internationally to contract research facilities in Bangalore, India. OS Therapies Incorporated maintains its principal executive offices in Grasonville, Maryland.
Summary of the business section of OS Therapies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- OS Therapies Inc
- Headquarters
- Rockville, MD
- Address
- 15825 Shady Grove Road, Suite 135 20850
- Phone
- (410) 297-7793
- Website
- ostherapies.com
- Employees
- 1,000, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- MaloneBailey, LLP, Houston, Texas
Stock & identifiers
- Ticker
- OSTX
- Exchange
- NYSE
- IPO date
- Aug 1, 2024
- Shares outstanding
- 46M, Aug 12, 2026
- Public float
- $49.60M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1795091
- CUSIP
- 68764Y207
- ISIN
- US68764Y2072
- FIGI
- BBG00Y71N7G7
- Share class FIGI
- BBG00Y71N7H6
- EIN
- 82-5118368
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Paul A. Romness | President and CEO, Director | 2,473,000 |
| Kerry M. Clem | Chief Commercial Officer | 225,000 |
| Knuettel Francis II | Chief Financial Officer | 270,000 |
| Robert Petit | See Remarks | 200,000 |
| Christopher P. Acevedo | Chief Financial Officer | 109,375 |
| Craig Eagle | Director | – |
| Olivier Roger Jarry | Director | – |
| Theodore F. Search | Director | 455,835 |
| John Ciccio | Director | 455,835 |
| Avril Suzette McKean-Dieser | Director | 5,000 |
| Karim Galzahr | Director | – |
| Colin Goddard | Director | 225,179 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Total | vs. prior year |
|---|---|---|---|---|---|
| Paul A. Romness President and Chief Executive Officer | $480.00K | $242.17K | $1.22M | $1.94M | +17% |
| Robert G. Petit Chief Medical and Scientific Officer | $420.00K | – | $610.00K | $1.03M | +13% |
| Christopher P. Acevedo Chief Financial Officer | $36.00K | – | $244.00K | $280.00K | -1% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 1, 2024
- Offer price
- $4.00
- Securities offered
- 1,600,000
- Gross proceeds
- $6.40M
- Exchange
- NYSE American
- First trading day
- Aug 1, 2024
- First-day close
- $2.51-37.3%
- Lock-up ends (est.)
- Jan 28, 2025
“The initial public offering price is $4.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“of Osteosarcoma is approximately 1,000 individuals annually in the United States and approximately 20,000 globally.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 15, 2026 | Late filing | Notification of late filing |
| Aug 15, 2025 | Late filing | Notification of late filing |
| Apr 15, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 14, 2024 | Late filing | Notification of late filing |
| Aug 1, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 30, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 15, 2024 | Late filing | Notification of late filing |
See a number that looks wrong?